Physician profile
John Zhang
NPI 1699947747
$1,954.43
in general payments reported to CMS, 2019-2025
17 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2022: $199 · 2023: $570 · 2024: $388 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $419.70 | 2022-2025 | Qulipta, Ubrelvy, Skyrizi |
| Janssen Biotech, INC. | $380.06 | 2022-2024 | Tremfya |
| Lilly USA, LLC | $302.39 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $194.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $127.60 | 2023-2025 | Dupixent |
| Nevro Corp. | $102.96 | 2019 | |
| Incyte Corporation | $79.85 | 2025 | Opzelura |
| Ucb, INC. | $65.78 | 2023-2024 | Bimzelx, Cimzia |
| Celgene Corporation | $55.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.55 | 2022-2025 | |
| Amgen INC. | $53.37 | 2019-2023 | Otezla, Enbrel |
| Biofrontera INC. | $23.67 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| Smith+Nephew, INC. | $23.19 | 2024 | Grafix Pl |
| Acera Surgical, INC. | $23.15 | 2022 | |
| Botanix Sb INC | $21.75 | 2025 | Sofdra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.12 | 2025 | Jublia, Siliq, Cabtreo |
| Mayne Pharma Commercial LLC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.